Application of immune checkpoint inhibitors in the treatment of small cell lung cancer

doi:10.3760/cma.j.cn371439-20210305-00148

Abstract

Abstract:

The emergence of immune checkpoint inhibitors (ICIs) have changed the pattern of anti-tumor therapy and brought new hope to the treatment of small cell lung cancer (SCLC). Currently, ICIs are most widely studied mainly include programmed death-1/ligand-1 and cytotoxic T-lymphocyte antigen-4. Altezumab is recommended for the first-line treatment of extensive SCLC, while pebrizizumab is recommended for the third-line treatment of extensive SCLC. There has been no breakthrough in the second-line and maintenance treatment of SCLC with ICIs.

Key words: Small cell lung carcinoma, Immune checkpoint inhibitors, PD-1, PD-L1, CTLA-4

Cao Chun, He Wenqi, Yan Jun. Application of immune checkpoint inhibitors in the treatment of small cell lung cancer[J]. Journal of International Oncology, 2021, 48(12): 747-750.

References 21

[1]	Oronsky B, Reid TR, Oronsky A, et al. What's new in SCLC? A review[J]. Neoplasia, 2017,19(10):842-847. DOI: 10.1016/j.neo.2017.07.007.
[2]	Qin H F, Wang F, Liu H, et al. New advances in immunotherapy for non-small cell lung cancer[J]. Am J Transl Res, 2018,10(8):2234-2245.
[3]	Li Y, Li F, Jiang F, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints[J]. Int J Mol Sci, 2016,17(7):1151. DOI: 10.3390/ijms17071151.
[4]	Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC)[J]. Pharmacol Ther, 2017,180:16-23. DOI: 10.1016/j.pharmthera.2017.06.002.
[5]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. New Engl J Med, 2012,366(26):2455-2465. DOI: 10.1056/NEJMoa1200694.
[6]	Wieder T, Eigentler T, Brenner E, et al. Immune checkpoint blockade therapy[J]. J Allergy Clin Immunol, 2018,142(5):1403-1414. DOI: 10.1016/j.jaci.2018.02.042.
[7]	Reck M, Heigener D, Reinmuth N. Immunotherapy for small-cell lung cancer: emerging evidence[J]. Future Oncol, 2016: 12(7):931-943. DOI: 10.2217/fon-2015-0012.
[8]	Horn L, Mansfeld AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018,379(23):2220-2229. DOI: 10.1056/NEJMoa1809064.
[9]	Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase ⅢKEYNOTE-604 study[J]. J Clin Oncol, 2020,38(21):2369-2379. DOI: 10.1200/JCO.20.00793.
[10]	Leal T, Wang Y, Dowlati A, et al. Randomized phase Ⅱ clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161[J]. J Clin Oncol, 2020,38(suppl_15):9000. DOI: 10.1200/JCO.2020.38.15_suppl.9000.
[11]	Reck M, Luft A, Szczesna A, et al. Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinm in extensive-stage small-cell lung cancer[J]. J Clin Oncol, 2016,34(31):3740-3748. DOI: 10.1200/JCO.2016.67.6601.
[12]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinu-metoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019,394(10212):1929-1939. DOI: 10.1016/s0140-6736(19)32222-6.
[13]	O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer[J]. J Clin Oncol, 2006,24(34):5441-5447. DOI: 10.1200/JCO.2006.06.5821.
[14]	Reck M, Vicente D, Ciuleanu T, et al. Efficacy and safety of ni-volumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from CheckMate 331[J]. Ann Oncol, 2018,29(10_Suppl):43. DOI: 10.1093/annonc/mdy511.004.
[15]	Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab inrecurrent small-cell lungcancer (CheckMate032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol, 2016,17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5.
[16]	Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive stage small cell lung cancer: results from the phase Ⅰb KEY-NOTE028 study[J]. J Clin Oncol, 2017,35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069.
[17]	Chung HC, Lopez-Martin JA, Kao SCH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158[J]. J Clin Oncol, 2018,36(Suppl_15):8506. DOI: 10.1200/JCO.2018.36.15_suppl.8506.
[18]	Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase Ⅱ study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)[J]. J Thorac Oncol. 2018,13(9):1393-1399 DOI: 10.1016/j.jtho.2018.05.002.
[19]	Riaz SP, Lüchtenborg M, Coupland VH, et al. Trends in incidence of small cell lung cancer and all lung cancer[J]. Lung Cancer, 2012,75(3):280-284. DOI: 10.1016/j.lungcan.2011.08.004.
[20]	Owonikoko TK, Kim HR, Govindan R, et al. Nivolumab (nivo) plus ipilimumab(ipi), nivo, or placebo(pbo) as maintenance therapy in patients(pts) with extensive disease small cell lung can-cer(ED-SCLC) after first-line(1L) platinum-based chemotherapy(chemo): results from the double-blind, randomized phase Ⅲ CheckMate 451 study[J]. Ann Oncol, 2019, 30(Suppl_2): ii77-ii80. DOI: 10.1093/annonc/mdz094.
[21]	Peters S, Pujol JL, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: results from the ETOP/IFCT4-12 STIMULI trial[J]. Ann Oncol, 2020,31(S4):S1211. DOI: 10.1016/j.annonc.2020.08.2326.